AzTrials
AzTrials

Joint Hypermobility SyndromeNCT05633225

Central Sensitization and Physical Activity in Adolescents With HSD/hEDS

An observational study of Joint Hypermobility Syndrome and Hypermobile Ehlers-Danlos Syndrome, run by Vastra Gotaland Region at 2 sites in Sweden.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Hypermobility Spectrum Disorder and hypermobile Ehlers-Danlos Syndrome (HSD/hEDS) is under-recognized and poorly understood and its management is therefore not clear. The goal of this study is to better understand pain and its impact on function in the daily activities of adolescents with Hypermobility Spectrum… Read more about this study

Who is it for?
Ages 13 to 17 yearsHealthy volunteers can take part
What is being tested?
Submax exercise test on a bicycle ergometer
How many people
100 participants
Where
2 sitesSweden
Study dates
25 Nov 2022to 31 Oct 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 13 to 17 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Study population: Adolecents diagnosed with HSD/hEDS, at Children's Primary Health Care Clinics in Gothenburg and Southern Bohuslän, and at Queen Silvia Children's Hospital and Skaraborgs hospital Skövde will be asked to participate. In addition, a control group of healthy pain free adolecents, matched for sex, age will be recruited from different schools in the region, throw hospital stuff and social media.

Who may be able to join

  • Able to read and understand Swedish
  • Diagnosed with HSD or hEDS
  • Able to read and understand Swedish
  • Healthy
  • Pain free at time of investigation (Numerical Rating Scale score <3/10).

Who cannot join

  • Pregnancy and one year postpartum.
  • Other syndromes with hypermobility such as the Marfan syndrome, Osteogenesis Imperfecta or other types of EDS.
  • Co-morbidity with neurological disorders
  • Pregnancy and one year postpartum.
  • Past or present signs of rheumatic, neurologic, musculoskeletal, metabolic diseases.
  • Chronic pain.

Trial locations and contacts

2 sites in 1 country.

Sweden2 sites
  • Sahlgrenska University Hospital

    Gothenburg, Region Västra Götaland, 416 85

  • Skaraborgs Hospital Skövde

    Skövde, Region Västra Götaland, 54142

Other trials in Sweden

About this study

Official title: Measuring Central Sensitization and Physical Activity in Adolescents With Hypermobility Spectrum Disorder or Hypermobile Ehlers-Danlos Syndrome

Hypermobility Spectrum Disorder and hypermobile Ehlers-Danlos Syndrome (HSD/hEDS) is under-recognized and poorly understood and its management is therefore not clear.

The goal of this study is to better understand pain and its impact on function in the daily activities of adolescents with Hypermobility Spectrum Disorder and/or hypermobile Ehlers-Danlos Syndrome.

This study will explore the presence of the pain sensitivity status after physical exercise as well as movement behaviour in adolescents with HSD/hEDS compared to a healthy control group.

Read the detailed description

All participants will be asked not to undertake physical exercise at least 48 hours before the measurements, and to refrain from consuming caffeine, alcohol or nicotine. For ethical reasons, the patients are allowed to take non-opioid pain medicine as described in the first step of the World Health Organization analgesic ladder (COX-inhibitors and paracetamol), however the patients will be asked to abstain from these medications during the 24 hours period before the measurements.

Being tested
Submax exercise test on a bicycle ergometer
Keywords
Pain, Hypermobility, Physical activity, Central sensitization, Fatigue, Ehlers Danlos Syndrome
Medical subject headings
Ehlers-Danlos syndrome type 3, Pain, Motor Activity, Fatigue, Ehlers-Danlos Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Submax exercise test on a bicycle ergometerOther

    To achieve exertion and not exhaustion, cycling will be stopped at 75% of the expected maximum heart rate (maximum heart rate of 220 beats per minute minus age) as a target value.

    If the participant then indicated that they do not feel strained, the cycling will continue until the participant experienced an effort on Borg Rating of Perceived Exertion Scale scale of 15 (hard).

Study groups in NCT05633225
Study groupRoleWhat they receive
Patient-groupNinety adolescents, 13-17 years of age Diagnosed with Hypermobility Spectrum Disorder or hypermobile Ehlers Danlos Syndrome.
Receives: Other: Submax exercise test on a bicycle ergometer
Control-groupNinety adolescents, 13-17 years of age. Participants have to be pain free at time of investigation (NRS score <3/10)
Receives: Other: Submax exercise test on a bicycle ergometer

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pressure Pain thresholds, primary and secondary hyperalgesia

    A hand-held pressure algometer (Wagner Instruments, FPX 25) will be used to assess pressure pain thresholds (PPT).

    The 1 cm2 rubber tip of the algometer will be positioned at an angle of 90 degrees in relation to the body part evaluated and pressure will be applied at a rate of 1 kg/s.

    PPT measurements will be carried out on the lower back in the supine position, on the tibialis anterior in the prone position, on the trapezius and deltoid while sitting.

    The participants will be instructed to say "stop" as soon as the sensation of a pressure changes to an uncomfortable feeling. The pressure algometer will be removed immediately and the recorded value will be noted.

    This procedure will be repeated time three times at each test location (30 seconds between each measurement). Average value of the last two measurements is used as the baseline.

    The order of the PPT measurement points will be randomized for each group.

    Measured: Baseline, pre-intervention

  2. Change of Pressure Pain thresholds, exercise-induced hyperalgesia

    Exercise-induced hyperalgesia will be measured by repeating the pressure pain thresholds (PPT) measures at the trapezius muscle and the tibialis anterior muscle (as described above) immediately after the performance of an submax exercise test on a bicycle ergometer

    The order of the PPT measurement points in the exercise-induced hyperalgesia measurements will be randomized for each group.

    Measured: Immediately after the intervention

Secondary outcomes (14)
  1. Numerical rating scale

    Average pain intensity will be measured using a 0-10 numerical rating scale (NRS) , with 0 = "no pain" and 10 = "worst possible pain" as the endpoint.

    Measured: Baseline, pre-intervention and immediately after the intervention

  2. Heart rate

    Peak heart rate immediately after a cycling test (heartbeat/min) will be recorded.

    Measured: Immediately after the intervention

  3. Borg Rating of Perceived Exertion Scale

    The subjective perceived effort of physical activity is measured with Borg Rating of Perceived Exertion Scale (Borg's RPE scale).

    Borg´s RPE measures physical activity intensity. Perceived exertion of how hard the individual feels the body is working. The individual experienced physical sensations during physical activity (increased heart rate, increased breathing or breathing rate, increased sweating and muscle fatigue)

    The scale goes from 6 "No effort at all" to 20 "Maximum effort" .

    Measured: Immediately after the intervention

  4. Medical examination

    Medical examination according to the 2017 criteria for Hypermobility Spectrum Disorder or HSD/hEDS (hEDS Diagnostic Checklist).

    Include assessment of joint mobility according to the Beighton scale (described below), physical examination of the diagnostic criteria for hEDS, family history of hEDS, and presence of musculoskeletal pain and joint dislocations.

    Measured: Baseline, pre-intervention

  5. Beighton scale

    The Beighton scale assesses 9 joints for hypermobility. Hyperextension in elbow joint bilaterally >10 degrees, hyperextension in knee joint bilaterally > 10 degrees, hyperextension of the fifth finger bilaterally > 90 degrees, ability to move the thumb towards the forearm bilaterally and trunk flexion in standing (palm completely on the surface).

    A total of 9 points is possible, generally hypermobility is achieved at 6 points for children and adolescence.

    Measured: Baseline, pre-intervention

  6. Demographics child

    Back ground data like age, sex ,onset, diagnosis, date of diagnosis, HSD/hED, family history of hypermobility, pain, physical activity habits, the impact of pain on school attendance, and other chronic diseases will be collected through a questionnaire.

    The questionnaire consists of 14 questions, of which 11 are multiple-choice questions, two with numerical rating scale answer options and one pain drawing.

    Measured: Baseline, pre-intervention

  7. Demographics caregiver

    Back ground data of the caregiver concerning education, type of employment and marital status, family history of pain, the caregiver's experience of the child's pain and physical activity level will be collected through a questionnaire.

    The questionnaire consists of 16 questions, of which 15 are multiple-choice questions, and one pain drawing.

    Measured: Baseline, pre-intervention

  8. Functional Disability Inventory

    Functional Disability Inventory (FDI) is a self-report inventory consisting of 15 items that are graded on a five-point scale, ranging from 0 to 4 ("No Trouble" to "Impossible"). The FDI assessed difficulties with the performance of daily activities in home, school, recreational, and social domains. Participants are asked to rate how much difficulty they had completing various tasks, "in the past few days". The sum of answers creates a total score (range 0-60) with higher scores indicating greater pain-related disability. The FDI was created for use in children and adolescents 8-17 years old with recurrent abdominal pain.

    Measured: Immediately after the intervention

  9. Frequency of Participation Questionnaire

    Participation will be measured using the Frequency of Participation Questionnaire (FPQ). The question is developed to measure the child's participation in all areas of the International Classification of Functioning, Disability and Health.

    FPQ consists of 14 questions about participation in everyday activities such as school and leisure.

    Participants indicate how often an activity is carried out. Grading from 0 ("never") to 5 ("a few times per week").

    Measured: Immediately after the intervention

  10. Multidimensional Fatigue Scale

    Fatigue will be measured with the Pediatric Quality of Life Inventory (PedsQL) Multidimensional Fatigue Scale.

    PedsQL Multidimensional Fatigue Scale is a self-assessment form that consists of 18 statements that are graded on a five-point scale, from 0 "never a problem" to 4 "almost always a problem". The PedsQL scale consists of three subscales: General Fatigue, Sleep/Rest Fatigue, and Cognitive Fatigue. The Child/Adolescents questionnaire includes ages, 5-7, 8-12 and 13-18.

    Items are reversed scored and linearly transformed to a 0-100 scale, so that higher scores indicate better outcome. To reverse score, the 0-4 scale items will be transformed to 0-100 as follows: 0=100, 1=75, 2=50, 3=25, 4=0.

    Measured: Immediately after the intervention

  11. Pain Catastrophizing scale

    Catastrophizing will be measured with the child version of the Pain Catastrophizing scale (PCS-C).

    The PCS-C is a self-assessment form that consists of 13 statements that are graded on a five-point scale, from 0 "not at all" to 4 "very much". The total score is 52 points where higher scores indicate higher catastrophizing thoughts. In agreement with previous study using PCS - C to investigate movement loss in children and their parents shared the result on PCS-C in this study into low (0-14 points), between.(15-25 points) and high (26-52) estimated disaster thoughts.

    Measured: Immediately after the intervention

  12. Hospital anxiety and depression scale

    Anxiety and depression will be measured with the Hospital anxiety and depression scale (HADS).

    HADS is a self-assessment form developed to measure anxiety and depression in patients in somatic care. HADS consists of 14 statements with seven statements for each subscale: HADS anxiety and HADS depression that are graded on a four-point scale from 0 to 3 points. The participant should decide how often he or she has known in the last week, for example "as if something terrible will happen" or whether he or she "appreciates the same things as before". The scores from the seven different statements per sub-scale are combined and can amount to a maximum of 21 points per sub-scale. 0-7 points: Does not speak for anxiety/depression, 8-10 points: The score may be an indication of an anxiety or depression condition in the person, 11 points or more: Demonstrate a likely depression or anxiety of clinical significance.

    Measured: Immediately after the intervention

  13. Physical activity

    Physical activity was measured with Axivity AX3 triaxial accelerometer (Axivity Ltd, UK).

    The participants were instructed to wear it attached to the right thigh with medical tape for seven days.

    Measured: Continuous measurement over seven days, immediately after the intervention

  14. Diary

    Participants will record planned physical activity and the time when they go to bed and get up parallel to the activity measurement.

    Measured: Continuous measurement over seven days, immediately after the intervention

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Dec 2022
  2. Study start25 Nov 2022
  3. Primary completion30 Jun 2023
  4. Study completion31 Oct 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
100 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05633225
Sponsor's protocol ID
CSaPhA-HSD/hEDS
Status last verified
Nov 2023
First submitted
19 Oct 2022
Last updated
7 Nov 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: There is not a plan to make IPD available.

Publications

  • Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med Genet. 2017 Mar;175(1):148-157. doi: 10.1002/ajmg.c.31539. Epub 2017 Feb 1.

    PubMed 28145606
  • Schubert-Hjalmarsson E, Fridolfsson J, Arvidsson D, Borjesson M, Lundberg M. Exploring physical activity patterns in adolescents with hypermobility spectrum disorder or hypermobile Ehlers-Danlos Syndrome. Pediatr Rheumatol Online J. 2025 Jul 8;23(1):69. doi: 10.1186/s12969-025-01124-0.

    PubMed 40629345

Questions about this trial

What is this clinical trial studying?

An observational study of Joint Hypermobility Syndrome and Hypermobile Ehlers-Danlos Syndrome, run by Vastra Gotaland Region at 2 sites in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pressure Pain thresholds, primary and secondary hyperalgesia (time frame: Baseline, pre-intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05633225, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Nov 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in